Tarig Elraiyah1, Mohamad Bassam Sonbol, Zhen Wang, Tagwa Khairalseed, Noor Asi, Chaitanya Undavalli, Mohammad Nabhan, Osama Altayar, Larry Prokop, Victor M Montori, Mohammad Hassan Murad. 1. Knowledge and Evaluation Research Unit (T.E., M.B.S., Z.W., T.K., N.A., C.U., M.N., O.A., V.M.M., M.H.M.), and Center for the Science of Healthcare Delivery (T.E., Z.W., N.A., M.H.M.), Mayo Clinic, Rochester, Minnesota 55905; Internal Medicine Department (M.B.S.), Georgia Regents University, Augusta, Georgia 30912; and Mayo Clinic Libraries (L.P.), Division of Endocrinology, Diabetes, Metabolism, and Nutrition (V.M.M.), and Division of Preventive, Occupational and Aerospace Medicine (M.H.M.), Mayo Clinic, Rochester, Minnesota 55905.
Abstract
CONTEXT: Exogenous dehydroepiandrosterone (DHEA) therapy has been proposed to replenish the depletion of endogenous DHEA and its sulfate form, which occurs with advancing age and is thought to be associated with loss of libido and menopausal symptoms. OBJECTIVE: We conducted a systematic review and meta-analysis to summarize the evidence supporting the use of systemic DHEA in postmenopausal women with normal adrenal function. METHODS: We searched MEDLINE, EMBASE, PsycInfo, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and Scopus through January 2014. Pairs of reviewers, working independently, selected studies and extracted data from eligible randomized controlled trials (RCTs). We used the random-effects model to pool across studies and evaluated heterogeneity using the I(2) statistic. RESULTS: We included 23 RCTs with moderate to high risk of bias enrolling 1188 women. DHEA use was not associated with significant improvement in libido or sexual function (standardized mean difference, 0.35; 95% confidence interval, -0.02 to 0.73; P value = .06; I(2) = 62%). There was also no significant effect of DHEA on serious adverse effects, serum lipids, serum glucose, weight, body mass index, or bone mineral density. This evidence warranted low confidence in the results, mostly due to imprecision, risk of bias, and inconsistency across RCTs. CONCLUSIONS: Evidence warranting low confidence suggests that DHEA administration does not significantly impact sexual symptoms or selected metabolic markers in postmenopausal women with normal adrenal function.
CONTEXT: Exogenous dehydroepiandrosterone (DHEA) therapy has been proposed to replenish the depletion of endogenous DHEA and its sulfate form, which occurs with advancing age and is thought to be associated with loss of libido and menopausal symptoms. OBJECTIVE: We conducted a systematic review and meta-analysis to summarize the evidence supporting the use of systemic DHEA in postmenopausal women with normal adrenal function. METHODS: We searched MEDLINE, EMBASE, PsycInfo, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and Scopus through January 2014. Pairs of reviewers, working independently, selected studies and extracted data from eligible randomized controlled trials (RCTs). We used the random-effects model to pool across studies and evaluated heterogeneity using the I(2) statistic. RESULTS: We included 23 RCTs with moderate to high risk of bias enrolling 1188 women. DHEA use was not associated with significant improvement in libido or sexual function (standardized mean difference, 0.35; 95% confidence interval, -0.02 to 0.73; P value = .06; I(2) = 62%). There was also no significant effect of DHEA on serious adverse effects, serum lipids, serum glucose, weight, body mass index, or bone mineral density. This evidence warranted low confidence in the results, mostly due to imprecision, risk of bias, and inconsistency across RCTs. CONCLUSIONS: Evidence warranting low confidence suggests that DHEA administration does not significantly impact sexual symptoms or selected metabolic markers in postmenopausal women with normal adrenal function.
Authors: K Sreekumaran Nair; Robert A Rizza; Peter O'Brien; Ketan Dhatariya; Kevin R Short; Ajay Nehra; Janet L Vittone; George G Klee; Ananda Basu; Rita Basu; Claudio Cobelli; Gianna Toffolo; Chiara Dalla Man; Donald J Tindall; L Joseph Melton; Glenn E Smith; Sundeep Khosla; Michael D Jensen Journal: N Engl J Med Date: 2006-10-19 Impact factor: 91.245
Authors: Manivannan Srinivasan; Brian A Irving; Robert L Frye; Peter O'Brien; Stacy J Hartman; Joseph P McConnell; K Sreekumaran Nair Journal: J Clin Endocrinol Metab Date: 2010-02-05 Impact factor: 5.958
Authors: Peter J Schmidt; Robert C Daly; Miki Bloch; Mark J Smith; Merry A Danaceau; Linda Simpson St Clair; Jean H Murphy; Nazli Haq; David R Rubinow Journal: Arch Gen Psychiatry Date: 2005-02
Authors: Jonathan A C Sterne; Alex J Sutton; John P A Ioannidis; Norma Terrin; David R Jones; Joseph Lau; James Carpenter; Gerta Rücker; Roger M Harbord; Christopher H Schmid; Jennifer Tetzlaff; Jonathan J Deeks; Jaime Peters; Petra Macaskill; Guido Schwarzer; Sue Duval; Douglas G Altman; David Moher; Julian P T Higgins Journal: BMJ Date: 2011-07-22
Authors: Mary Panjari; Robin J Bell; Fiona Jane; Rory Wolfe; Jenny Adams; Corallee Morrow; Susan R Davis Journal: J Sex Med Date: 2009-07-10 Impact factor: 3.802
Authors: Annewieke W van den Beld; Jean-Marc Kaufman; M Carola Zillikens; Steven W J Lamberts; Josephine M Egan; Aart J van der Lely Journal: Lancet Diabetes Endocrinol Date: 2018-07-17 Impact factor: 32.069
Authors: Catherine Kim; Dana Dabelea; Rita R Kalyani; Costas A Christophi; George A Bray; Xavier Pi-Sunyer; Christine H Darwin; Swaytha Yalamanchi; Elizabeth Barrett-Connor; Sherita Hill Golden; Edward J Boyko Journal: J Clin Endocrinol Metab Date: 2017-09-01 Impact factor: 5.958
Authors: Kurt W Prins; Thenappan Thenappan; E Kenneth Weir; Rajat Kalra; Marc Pritzker; Stephen L Archer Journal: J Am Heart Assoc Date: 2019-01-08 Impact factor: 5.501
Authors: Catherine Kim; Vanita R Aroda; Ronald B Goldberg; Naji Younes; Sharon L Edelstein; Mary Lou Carrion-Petersen; David A Ehrmann Journal: J Clin Endocrinol Metab Date: 2018-05-01 Impact factor: 5.958